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Dear Editor,
While in Burkitt lymphoma (BL) immunochemotherapy readily
induces remissions, the clinical outcomes for patients with refrac-
tory or recurrent disease are still adverse [1, 2]. The phosphatidyl-
inositol-3 kinase (PI3K) signal transduction pathway is involved
in the activation, proliferation, and migration of B lymphocytes,
and a cooperation of MYC and PI3K has been described in BL
oncogenesis. Idelalisib is a highly selective inhibitor of the PI3K
delta isoform [3] with significant clinical activity against indolent
B cell lymphomas [4, 5]. We here report the successful salvage
therapy with idelalisib in a patient with relapsed
immunodeficiency-associated BL exhibiting a TP53 mutation
and a H1047R mutation in the PIK3CA gene.
The initial diagnosis of stage IIIB BL disease and concurrent
HIV-1 positivity was made in a 65-year-old male patient with
multifocal lymphadenopathy and B-symptoms. The patient was
started on immediate anti-viral therapy.At initial presentation, the
patient appeared ineligible for multiphase leukemia-based regi-
mens due to comorbidities (ischemic heart disease, impaired re-
nal function), so that he received one course of R-CHOP, and
upon adequate tolerance and response, further seven courses of
R-CHOEP-21, inducing a complete remission. Ten months from
initial diagnosis, relapse manifested as an isolated cutaneous
manifestation (3 × 5 cm) in the upper thigh. Two courses of
platine/Ara-C-based chemotherapy (R-DHAP) induced partial
remission, consolidated by involved site radiotherapy. Fifteen
months after initial diagnosis the disease recurred again, at this
time refractory to methotrexate/Ara-C-based chemotherapy
(dexamethasone 20 mg p.o., etoposide 60 mg/m2 d4 + 5 i.v.,
cytarabine 60 mg/m2 d4 + 5 i.v.; ifosfamide 400 mg/m2 d1–5
i.v.; methotrexate 500 mg/m2 i.v., methotrexate 12 mg i.th. d3).
Additional radiotherapy and vinblastine every other week was
started in palliative intention. Responding to the patient’s wish
for further treatment, off-label idelalisib was initiated (150 mg
bid) inducing shrinkage of the tumor (Fig. 1a, b) and decline of
plasma LDH (Fig. 1c). Idelalisib was continued without infec-
tious complications or adverse reactions for 10 months, until the
tumor recurred and the patient succumbed to progressive disease.
Analysis of the initial lymphoma by high-throughput
sequencing (HTS) detected a TP53 mutation (T175H, VAF
83.5%), compatible with coincident structural loss of the second
TP53 allele and presumably representing the major unfavorable
molecular factor in this case [6–8]. In addition, we identified two
mutations in the catalytic alpha subunit of the PIK3CA gene, i.e.,
p.H1047R (variant allele frequency (VAF) 5.0%) and p.Q1033R
(VAF 3.7%) affecting exon 21 on the same allele. This PIK3CA
H1047R mutation affects the highly conserved catalytic subunit
p110a and has previously been identified at high frequency in
many types of solid tumors [9, 10]. In patients receiving
PI3K/AKT/mTOR inhibitors, the presence of the PIK3CA
H1047R mutation was associated with improved response rates
compared with patients with wild-type PIK3CA or other
PIK3CA mutations (38% vs. 10% vs. 13%) [11]. So far,
PIK3CA H1047R mutations have not been described in BL cell
* Annalen Bleckmann
annalen.bleckmann@ukmuenster.de
1 Department of Haematology and Medical Oncology, University
Medicine Göttingen, Göttingen, Germany
2 Department of Medicine A, Hematology, Oncology and
Pneumology, University Hospital Münster, Münster, Germany
3 Department of Pathology, University Medicine Göttingen,
Göttingen, Germany
4 Department of Radiology, University Medicine Göttingen,
Göttingen, Germany
5 Department of Hematology and Central Hematology Laboratory,
Inselspital, Bern University Hospital, University of Bern,
Bern, Switzerland
Annals of Hematology
https://doi.org/10.1007/s00277-020-03974-y
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
14
44
72
 
| 
do
wn
lo
ad
ed
: 
20
.6
.2
02
0
lines or primary tumor samples. However, preclinical evidence
demonstrated that deregulatedMYC and PI3K activity synergize
in BL pathogenesis [8], and that pathway inhibitors suppress
PI3K-dependent proliferation of human BL cells [12, 13]. We
speculate, that in the case of the index patient, the PIK3CA
H1047R mutation was a lymphoma propagating factor by coop-
eration of MYC/IgH and PIK3CA [14].
In conclusion, our report supports further exploration of
PI3K inhibition in the treatment of patients with refractory/
relapsed BL. Screening for PIK3CA mutations may allow the
detection of specific lymphoma cell vulnerabilities for
targeted therapy in relapsed/refractory disease.
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